The beat-and-raise quarter with strong HVP and biologics growth confirms accelerating demand for West's high-value injectable components. Traders should watch for continued margin expansion and any updates on the SmartDose sale to AbbVie. The raised guidance provides a clear upward catalyst for the stock in the near term.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 23 $355.48entry
- T+1 · 4mo ago −7.67%α −7.78% · $328.20
- T+5 · 4mo ago −4.47%α −4.95% · $339.59
- T+20 · 3mo ago −0.48%α −3.79% · $353.77
- T+60 · 5w ago +7.75%α +3.19% · $383.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating consensus estimates of $840M and $2.08. The company raised full-year 2026 adjusted-diluted EPS guidance to $8.85-$9.05 (from $8.40-$8.75) and net sales guidance to $3.345B-$3.380B, driven by strong HVP Components (+19.4%) and Biologics (+30.3%) growth. The beat and raised guidance signal accelerating demand for injectable solutions, particularly in GLP-1 and biologics, making this a clear positive catalyst for the stock.
Key Financial Metrics
Key Facts
- Q2 2026 net sales of $872.3M beat $840M consensus (+3.8% surprise)
- Diluted EPS of $2.15 beat $2.08 consensus (+3.4% surprise)
- Adjusted-diluted EPS of $2.37 increased 28.8% YoY
- Full-year 2026 adjusted-diluted EPS guidance raised to $8.85-$9.05 from $8.40-$8.75
- Full-year 2026 net sales guidance raised to $3.345B-$3.380B from $3.295B-$3.350B
- HVP Components net sales grew 19.4% to $424.1M, 49% of total sales
- Biologics market group net sales grew 30.3% to $374.8M
- Operating cash flow was $213.9M; free cash flow was $128.0M
- Company repurchased 1.8M shares for $454.3M in H1 2026
Financial Impact
Beat consensus by $32.3M on revenue and $0.07 on EPS; raised full-year EPS guidance by $0.45 at midpoint
Risk Factors
- SmartDose 3.5mL sale to AbbVie creates a $55M revenue headwind in H2 2026
- Foreign exchange headwinds of ~1% on full-year guidance
- Cost-method investment impairment of $3.5M in Q2
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302832704 |
Track record
17 reports on WST
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $392.48 Now $417.80 +6.45% settles Feb 3
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $416.67 Now $417.80 +0.27% settles Jan 27
- Oct 26, 202621d ago 8-K Neutral 4/10 Entry $398.29 Now $417.80 +4.90% settles Jan 25
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $394.73 Now $417.80 +5.84% settles Jan 22
- Jul 23, 202616w ago 8-K Bullish 7/10 No price data
- Jul 23, 202616w ago Press Release Bullish 7/10 Viewing Entry $355.48 to $383.02 Now $417.80 +17.53% ▲ +7.75% +3.19% vs SPY
- Jul 7, 202618w ago Press Release Neutral 1/10 Entry $356.08 to $370.76 Now $417.80 +17.33% ▲ +4.12% +2.13% vs SPY
- May 11, 202627w ago 8-K Bearish 7/10 Entry $311.82 to $348.06 Now $417.80 −33.99% ▼ −11.62% −7.51% vs SPY
- Apr 27, 202629w ago Insider Cluster Neutral 2/10 Entry $300.93 to $358.41 Now $417.80 +38.83% ▲ +19.10% +14.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers